Effects of carbidopa and entacapone on the metabolic fate of the norepinephrine prodrug L-DOPS

Journal of Clinical Pharmacology

Volumn 51, Issue 1, 2011, Pages 66-74

  Goldstein, David S ^a   Holmes, Courtney ^a   Sewell, Latoya ^a   Pechnik, Sandra ^a   Kopin, Irwin J ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

autonomic failure; DHPG; dihydroxymandelic acid; dihydroxyphenylglycol; Dihydroxyphenylserine; DOPS; norepinephrine; orthostatic hypotension; Parkinson's disease

Indexed keywords

3,4 DIHYDROXYPHENYLETHYLENE GLYCOL; CARBIDOPA; DIHYDROXYMANDELIC ACID; DRUG METABOLITE; ENTACAPONE; NORADRENALIN; PLACEBO; PRODRUG; THREO 3,4 DIHYDROXYPHENYLSERINE; UNCLASSIFIED DRUG;

AGED; ARTICLE; AUTONOMIC DYSFUNCTION; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CONTROLLED STUDY; DEAMINATION; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; HEART RATE; HUMAN; MALE; METHYLATION; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRESSOR RESPONSE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SYSTEMIC CIRCULATION; VASOCONSTRICTION;

AGED; ANTIPARKINSON AGENTS; BLOOD PRESSURE; CARBIDOPA; CATECHOLS; DOUBLE-BLIND METHOD; DROXIDOPA; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; NITRILES; NOREPINEPHRINE; PARKINSON DISEASE; PRODRUGS; PURE AUTONOMIC FAILURE; VASOCONSTRICTION;

EID: 78650852284     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010363476     Document Type: Article

References (19)

1. Kaufmann H., Saadia D., Voustianiouk A., et al. Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation. 2003 ; 108: 724-728.
2. Blaschko H., Burn JH, Langemann H. The formation of noradrenaline from dihydroxyphenylserine. Br J Pharmacol Chemother. 1950 ; 5: 431-437.
3. Zarow C., Lyness SA, Mortimer JA, Chui HC Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol. 2003 ; 60: 337-341.
4. Amino T., Orimo S., Takahashi A., Uchihara T., Mizusawa H. Profound cardiac sympathetic denervation occurs in Parkinson disease. Brain Pathol. 2005 ; 15: 29-34.
5. Ziegler MG, Lake CR, Kopin IJ The sympathetic-nervous-system defect in primary orthostatic hypotension. N Engl J Med. 1977 ; 296: 293-297.
6. Allcock LM, Ullyart K., Kenny RA, Burn DJ Frequency of orthostatic hypotension in a community based cohort of patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2004 ; 75: 1470-1471.
7. Goldstein DS, Eldadah BA, Holmes C., et al. Neurocirculatory abnormalities in Parkinson disease with orthostatic hypotension: independence from levodopa treatment. Hypertension. 2005 ; 46: 1-7.
8. Kawamura M., Eisenhofer G., Kopin IJ, et al. Aldose reductase: an aldehyde scavenging enzyme in the intraneuronal metabolism of norepinephrine in human sympathetic ganglia. Auton Neurosci. 2002 ; 96: 131-139.
9. Eisenhofer G., Goldstein DS, Stull R., Ropchak TG, Keiser HR, Kopin IJ Dihydroxyphenylglycol and dihydroxymandelic acid during intravenous infusions of noradrenaline. Clin Sci. 1987 ; 73: 123-125.
10. Goldstein DS, Tack C. Non-invasive detection of sympathetic neurocirculatory failure. Clin Auton Res. 2000 ; 10: 285-291.
11. Goldstein DS, Holmes C., Kaufmann H., Freeman R. Clinical pharmacokinetics of the norepinephrine precursor L-threo-DOPS in primary chronic autonomic failure. Clin Auton Res. 2004 ; 14: 363-368.
12. Holmes C., Eisenhofer G., Goldstein DS Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection. J Chromatog B Biomed Applic. 1994 ; 653: 131-138.
13. Kawamura M., Kopin IJ, Kador PF, Sato S., Tjurmina O., Eisenhofer G. Effects of aldehyde/aldose reductase inhibition on neuronal metabolism of norepinephrine. J Auton Nerv Syst. 1997 ; 66: 145-148.
14. Goldstein D., Horwitz D., Keiser HR, Polinsky RJ, Kopin IJ Plasma l-[3H]norepinephrine, d-[14C]norepinephrine, and d,l-[3H]isoproterenol kinetics in essential hypertension. J Clin Invest. 1983 ; 72: 1748-1758.
15. Eisenhofer G., Goldstein DS, Ropchak TG, Nguyen HQ, Keiser HR, Kopin IJ Source and physiological significance of plasma 3,4-dihydroxyphenylglycol and 3-methoxy-4-hydroxyphenylglycol. J Auton Nerv Syst. 1988 ; 24: 1-14.
16. Polinsky RJ, Kopin IJ, Ebert MH, Weise V. Pharmacologic distinction of different orthostatic hypotension syndromes. Neurology. 1981 ; 31: 1-7.
17. Senard JM, Valet P., Durrieu G., et al. Adrenergic supersensitivity in parkinsonians with orthostatic hypotension. Eur J Clin Invest. 1990 ; 20: 613-619.
18. Burke WJ, Li SW, Chung HD, et al. Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: Role in neurodegenerative diseases. Neurotoxicology. 2004 ; 25: 101-115.
19. Goldstein DS, Eisenhofer G., Stull R., Folio CJ, Keiser HR, Kopin IJ Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans. J Clin Invest. 1988 ; 81: 213-220.